跳至主要内容
临床试验/NCT02984137
NCT02984137已完成不适用

A Prospective Longitudinal Neuroimaging and Biomarker Cohort Study in Idiopathic Rapid Eye Movement(REM) Sleep Behavior Disorder

Seoul National University Hospital2 个研究点 分布在 2 个国家目标入组 80 人开始时间: 2013年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
80
试验地点
2
主要终点
Frequency of development of Lewy body diseases

研究概览

简要总结

This is a prospective cohort study to evaluate degenerative changes in the brain by performing functional imaging analysis in patients with RBD and its correlations with clinical symptoms and dopaminergic degeneration. This study also evaluates cognitive changes with functional imaging measures and olfactory and other premotor symptoms of Lewy body disease. This study also collects gene extracts and sera to develop a biomarker for early detection of neurodegeneration.

详细描述

This study will include 3 groups in relation with RBD: idiopathic RBD (iRBD), PD- RBD, normal controls without RBD. In all groups, neurological examinations, olfactory testings, nonmotor symptoms evaluations, neuropsychological evaluations (detailed outcomes are in the outcome section) will be performed at baseline evaluation after enrollment. Image data will be obtained on following modalities: brain magnetic resonance imaging (MRI), 18F-N-ω-fluoropropyl- 2β-carbomethoxy- 3β-(4-iodophenyl) nortropane ([18F]FP-CIT) positron emission tomography (PET), and 18F-fludeoxyglucose([18F]FDG) PET.

To assess progression toward Lewy body disorders, patients in iRBD group will be evaluated at 2, and 4 years of follow-up visit. Clinical, neuropsychological tests, brain MRI, and two PET scans will be administered. After 4 years, patients who are willing to participate will be additionally followed-up yearly as a routine clinical visit with clinical and neurological examinations until obvious signs of Lewy body diseases will develop.

In PD-RBD group, patients will be evaluated at 3-year follow-up period amongst days of routine clinic visits with administering clinical and neuropsychological tests.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • iRBD group:
  • A diagnosis of RBD according to the international classification of sleep disorders-2 (ICSD-2) criteria
  • No current neurological diseases related with RBD
  • Male or female aged from 30 to 80 years old at screening
  • Subject enrolled voluntarily and understood the contents of the study
  • A diagnosis of PD according to the UK Brain Bank Diagnostic Criteria
  • A diagnosis of RBD according to the international classification of sleep disorders-2 (ICSD-2) criteria
  • Male or female aged from 30 to 80 years old at screening
  • Subject enrolled voluntarily and understood the contents of the study
  • Control group:
  • No current neurological or psychiatric diseases related with RBD
  • Male or female aged from 30 to 80 years old at screening
  • Age and sex matched with those of subjects in iRBD group
  • Subject enrolled voluntarily and understood the contents of the study

排除标准

  • Clinically significant cognitive decline unable to follow the study (Mini-mental state examination [MMSE] score less than 20)
  • History of psychiatric illnesses (ex. depression)
  • Unable to walk and cooperate to the examination
  • Unable to take magnetic resonance imaging or positron emission tomography
  • Existence of illness or problems which makes difficult to be enrolled to the study judged by clinicians

结局指标

主要结局

Frequency of development of Lewy body diseases

时间窗: up to 4-years follow-up

idiopathic RBD group only

次要结局

  • Parkinsonian motor symptoms score change measured by the unified Parkinson's disease rating scale (MDS-UPDRS)(from baseline to 2-years and 4-years follow-up (iRBD group), to 3-years follow-up (PD-RBD group))
  • Nonmotor symptoms profile change assessed by a combined evaluatin using the non-motor symptom scale and part I of the MDS-UPDRS(from baseline to 2-years and 4-years follow-up (iRBD group), to 3-years follow-up (PD-RBD group))
  • Cognitive change measured by the neuropsychological test battery(from baseline to 2-years ad 4-years follow-up (iRBD group), to 3-years follow-up (PD-RBD group))
  • Degenerative brain changes predicted by MRI (diffusion tensor analysis and volumetry)(from baseline to 2-years and 4-years follow-up (iRBD group only))
  • Degenerative brain changes predicted by [18F]FP-CIT PET(from baseline to 2-years and 4-years follow-up (iRBD group only))
  • Functional network changes predicted by the resting-state functional MRI(from baseline to 2-years and 4-years follow-up (iRBD group only))
  • Functional network changes predicted by [18F]FDG PET(from baseline to 2-years and 4-years follow-up (iRBD group only))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jee-Young Lee

Associate Professor

Seoul National University Hospital

研究点 (2)

Loading locations...

相似试验